211 related articles for article (PubMed ID: 17486268)
1. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate.
Saad F; Kamischke A; Yassin A; Zitzmann M; Schubert M; Jockenhel F; Behre HM; Gooren L; Nieschlag E
Asian J Androl; 2007 May; 9(3):291-7. PubMed ID: 17486268
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
[TBL] [Abstract][Full Text] [Related]
3. Testosterone depot injection in male hypogonadism: a critical appraisal.
Yassin AA; Haffejee M
Clin Interv Aging; 2007; 2(4):577-90. PubMed ID: 18225458
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
Wang C; Harnett M; Dobs AS; Swerdloff RS
J Androl; 2010; 31(5):457-65. PubMed ID: 20133964
[TBL] [Abstract][Full Text] [Related]
5. Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study.
Morgentaler A; Dobs AS; Kaufman JM; Miner MM; Shabsigh R; Swerdloff RS; Wang C
J Urol; 2008 Dec; 180(6):2307-13. PubMed ID: 18930255
[TBL] [Abstract][Full Text] [Related]
6. Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate.
Yassin AA; Saad F
Andrologia; 2007 Oct; 39(5):181-4. PubMed ID: 17714216
[TBL] [Abstract][Full Text] [Related]
7. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
[TBL] [Abstract][Full Text] [Related]
8. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
von Eckardstein S; Nieschlag E
J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
[TBL] [Abstract][Full Text] [Related]
9. Effects of various modes of androgen substitution therapy on erythropoiesis.
Jockenhövel F; Vogel E; Reinhardt W; Reinwein D
Eur J Med Res; 1997 Jul; 2(7):293-8. PubMed ID: 9233903
[TBL] [Abstract][Full Text] [Related]
10. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate.
Saad F; Gooren LJ; Haider A; Yassin A
J Androl; 2008; 29(1):102-5. PubMed ID: 17916569
[TBL] [Abstract][Full Text] [Related]
11. Testosterone undecanoate in the treatment of male hypogonadism.
Edelstein D; Basaria S
Expert Opin Pharmacother; 2010 Aug; 11(12):2095-106. PubMed ID: 20642374
[TBL] [Abstract][Full Text] [Related]
12. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies.
Behre HM; Abshagen K; Oettel M; Hübler D; Nieschlag E
Eur J Endocrinol; 1999 May; 140(5):414-9. PubMed ID: 10229906
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men.
Qoubaitary A; Meriggiola C; Ng CM; Lumbreras L; Cerpolini S; Pelusi G; Christensen PD; Hull L; Swerdloff RS; Wang C
J Androl; 2006; 27(6):853-67. PubMed ID: 16837736
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
Moon DG; Park MG; Lee SW; Park K; Park JK; Kim SW; Park NC; Ahn TY; Paick JS; Seo JT; Yang DY; Lee JY; Kim JJ
J Sex Med; 2010 Jun; 7(6):2253-2260. PubMed ID: 20345732
[TBL] [Abstract][Full Text] [Related]
15. Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido).
Yassin AA; Saad F
World J Urol; 2006 Dec; 24(6):639-44. PubMed ID: 17048032
[TBL] [Abstract][Full Text] [Related]
16. A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate.
Minnemann T; Schubert M; Hübler D; Gouni-Berthold I; Freude S; Schumann C; Oettel M; Ernst M; Mellinger U; Sommer F; Krone W; Jockenhövel F
Aging Male; 2007 Sep; 10(3):155-8. PubMed ID: 17701659
[TBL] [Abstract][Full Text] [Related]
17. Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome.
Saad F; Gooren L; Haider A; Yassin A
Andrologia; 2008 Feb; 40(1):44-8. PubMed ID: 18211301
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.
Zitzmann M; Nieschlag E
J Clin Endocrinol Metab; 2007 Oct; 92(10):3844-53. PubMed ID: 17635942
[TBL] [Abstract][Full Text] [Related]
19. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
Giagulli VA; Triggiani V; Carbone MD; Corona G; Tafaro E; Licchelli B; Guastamacchia E
J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
[TBL] [Abstract][Full Text] [Related]
20. Randomized cross-over clinical trial of injectable vs. implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men.
Fennell C; Sartorius G; Ly LP; Turner L; Liu PY; Conway AJ; Handelsman DJ
Clin Endocrinol (Oxf); 2010 Jul; 73(1):102-9. PubMed ID: 19891698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
